Diffuse Large B-Cell Lymphoma Therapeutics Market Report 2025

The diffuse large B-cell lymphoma therapeutics market size has grown strongly in recent years. It will grow from $4.74 billion in 2024 to $5.15 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to clinical research advances, regulatory approvals, patient awareness and diagnosis, collaborative initiatives, standard of care evolution.

The diffuse large B-cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to biomarker discovery, immunotherapy advancements, rising incidence rates, global aging population, healthcare infrastructure development, expanded access to novel drugs. Major trends in the forecast period include rise of outpatient treatment settings, collaborative clinical trials, patient-centric care models, advances in diagnostic imaging, healthcare digitalization.

The rising prevalence of diffuse large B-cell lymphoma (DLBCL) is anticipated to propel the expansion of the diffuse large B-cell lymphoma therapeutics market. DLBCL, an aggressive form of non-Hodgkin lymphoma originating from B-cells in the lymphatic system, is characterized by rapid and diffuse growth. The therapeutics developed for DLBCL aim to enhance outcomes for diagnosed individuals by effectively targeting and managing cancer cells. Notably, the American Cancer Society's 2023 estimates project approximately 80,550 new non-Hodgkin's lymphoma cases, underscoring the urgent need for advancements in therapeutic solutions. This increasing incidence serves as a catalyst for the growth of the diffuse large B-cell lymphoma therapeutics market.

The anticipated growth of the diffuse large B-cell lymphoma (DLBCL) therapeutics market is closely tied to the increasing adoption of personalized medicine. Personalized medicine, an innovative healthcare approach, tailors medical interventions to the unique characteristics of each patient, including genetic and molecular profiles. This approach facilitates the development of targeted therapies specifically addressing the heterogeneity of DLBCL subtypes. Biomarker-driven treatment strategies and companion diagnostics play a pivotal role in identifying patients likely to benefit from specific therapies, thus enhancing overall treatment efficacy. Noteworthy is the fact that in 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% (12 NMEs) classified as personalized medicines by the Personalized Medicine Coalition (PMC). The increasing adoption of personalized medicine emerges as a significant driver for the growth of the diffuse large B-cell lymphoma therapeutics market.

The diffuse large B-cell lymphoma (DLBCL) therapeutics market is witnessing a notable trend marked by the increasing emphasis on the development of therapeutic drugs. Key players within this market are actively engaged in the research and development of novel drugs to bolster their standing and competitiveness. A pertinent example is Bristol-Myers Squibb, a prominent US-based pharmaceutical company dedicated to drug research and development. In June 2022, the company secured approval from the US FDA for CAR T Cell Therapy Breyanzi. This approval extended the application of Breyanzi to encompass the treatment of patients with diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), and relapsed or refractory large B-cell lymphoma. Breyanzi, characterized as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, is designed to cater to a diverse patient population, including those with primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B.

A pivotal strategy employed by major players in the diffuse large B-cell lymphoma (DLBCL) therapeutics market involves the continuous development of new drugs to secure a competitive advantage. Illustratively, in June 2023, MINJUVI (tafasitamab), a product of Specialised Therapeutics Asia Pte Ltd (STA), a Singapore-based biopharmaceutical company, received approval from the Therapeutic Goods Administration (TGA). Indicated for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT), MINJUVI, in combination with lenalidomide, functions as a CD19-targeting immunotherapy, triggering an immune response against B-cell lymphoma cells. The drug has demonstrated a favorable side effect profile and achieved high response rates in patients with relapsed disease. Its approval through a provisional regulatory pathway and participation in the Modified Project Orbis initiative underscore the concerted efforts to expedite availability for Australian patients. The decision was informed by positive data from the Phase 2 L-MIND study, with ongoing approval contingent on findings from the confirmatory Phase 3 frontMIND study.

In August 2022, Ipsen, a prominent biopharmaceutical company based in France, successfully acquired Epizyme Inc. The financial details of the acquisition were not disclosed. This acquisition has proven instrumental in empowering Ipsen to diversify and enhance its oncology portfolio. Notably, the integration of Epizyme's Tazverik, a groundbreaking EZH2 inhibitor, has fortified Ipsen's commitment to providing innovative treatments. This strategic expansion has further augmented Ipsen's capabilities within the oncology sector, positioning the company as a key player in delivering advanced therapeutic solutions. Epizyme Inc., a US-based biopharmaceutical company specializing in the development and marketing of epigenetic therapies for cancer and other diseases, brought valuable expertise and assets to Ipsen through this strategic acquisition.

Major companies operating in the diffuse large B-cell lymphoma therapeutics market include Novartis AG, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, CTI BioPharma Corp., Celltrion Healthcare Co Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences Inc., Seagen Inc., Kite Pharma Inc., ADC Therapeutics SA, Bayer AG, Xencor Inc., Autolus Therapeutics plc, Allogene Therapeutics Inc., Spectrum Pharmaceuticals Inc., AstraZeneca PLC, Aptevo Therapeutics Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Celgene Corporation, Eli Lilly and Company, Sanofi SA, Seattle Genetics Inc., Karyopharm Therapeutics Inc., TG Therapeutics Inc., MorphoSys AG.

North America was the largest region in the global diffuse large B-cell lymphoma therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diffuse large b-cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diffuse large b-cell lymphoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Diffuse large B-cell lymphoma therapeutics encompass the strategies and pharmaceutical interventions employed to address and counteract diffuse large B-cell lymphoma, an aggressive subtype of non-Hodgkin lymphoma characterized by the rapid proliferation of malignant B-cells.

Key pharmaceutical categories integral to the treatment of diffuse large B-cell lymphoma include cisplatin, carboplatin, 5-fluorouracil (5-FU), docetaxel (Taxotere), paclitaxel (Taxol), methotrexate, among others. Cisplatin is a chemotherapeutic agent utilized across various malignancies due to its mechanism of disrupting cancer cell DNA, thereby impeding their proliferative capacity. In the context of lymphoma management, cisplatin is often incorporated into combination chemotherapy protocols. The therapeutic regimen encompasses a spectrum of modalities such as targeted therapy, immunotherapy, and chemotherapy, administered via oral, parenteral, and alternative routes. These treatments are typically dispensed within hospital and clinical settings.

The diffuse large B-cell lymphoma market research report is one of a series of new reports that provides diffuse large B-cell lymphoma market statistics, including the diffuse large B-cell lymphoma industry global market size, regional shares, competitors with a diffuse large B-cell lymphoma market share, detailed diffuse large B-cell lymphoma market segments, market trends, and opportunities, and any further data you may need to thrive in the diffuse large B-cell lymphoma industry. This diffuse large B-cell lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The diffuse large B-cell lymphoma therapeutics market consists of revenues earned by entities by providing R-CHOP (rituximab (Rituxan), cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Oncovin), and prednisone therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The diffuse large B-cell lymphoma therapeutics market also includes sales of diagnostic devices, radiation therapy equipment, surgical instruments, and devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.